# Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive Cohort

> **NCT00824850** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 75 (actual)

## Conditions studied

- Pneumococcal Conjugate Vaccine

## Interventions

- **BIOLOGICAL:** 13-valent Pneumococcal Conjugate Vaccine
- **BIOLOGICAL:** 13-valent Pneumococcal Conjugate Vaccine

## Key facts

- **NCT ID:** NCT00824850
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2011-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00824850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00824850, "Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive Cohort". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00824850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*